Abstract
Background Many patients have unexplained persistent dyspnea after negative computed tomographic pulmonary angiography (CTPA). We hypothesized that many of these patients have isolated right ventricular (RV) dysfunction from treatable causes. We previously derived a clinical decision rule (CDR) for predicting RV dysfunction consisting of persistent dyspnea and normal CTPA, finding that 53% of CDR-positive patients had isolated RV dysfunction. Our goal is to validate this previously derived CDR by measuring the prevalence of RV dysfunction and outcomes in dyspneic emergency department patients. Methods A secondary analysis of a prospective observational multicenter study that enrolled patients presenting with suspected PE was performed. We included patients with persistent dyspnea, a nonsignificant CTPA, and formal echo performed. Right ventricular dysfunction was defined as RV hypokinesis and/or dilation with or without moderate to severe tricuspid regurgitation. Results A total of 7940 patients were enrolled. Two thousand six hundred sixteen patients were analyzed after excluding patients without persistent dyspnea and those with a significant finding on CTPA. One hundred ninety eight patients had echocardiography performed as standard care. Of those, 19% (95% confidence interval [CI], 14%-25%) and 33% (95% CI, 25%-42%) exhibited RV dysfunction and isolated RV dysfunction, respectively. Patients with isolated RV dysfunction or overload were more likely than those without RV dysfunction to have a return visit to the emergency department within 45 days for the same complaint (39% vs 18%; 95% CI of the difference, 4%-38%). Conclusion This simple clinical prediction rule predicted a 33% prevalence of isolated RV dysfunction or overload. Patients with isolated RV dysfunction had higher recidivism rates and a trend toward worse outcomes.
Original language | English (US) |
---|---|
Pages (from-to) | 542-547 |
Number of pages | 6 |
Journal | American Journal of Emergency Medicine |
Volume | 33 |
Issue number | 4 |
DOIs | |
State | Published - Apr 1 2015 |
Funding
Christopher L. Moore has a $4000 honorarium/consulting fee from Philips to work on developing an online tutorial for bedside echo in PE. D. Mark Courtney is on the Janssen pharmaceuticals advisory board and has had previous grant support from the National Institutes of Health for PE research. Christopher Kabhrel has grant funding from the NIH, Stago Diagnostics and Siemen's Healthcare; is a consultant for Genentech and Janssen pharmaceuticals. Jeffrey A. Kline has grant funding from the National Institutes of Health and Ikaria; is a consultant for Genentech, Stago Diagnostics, and Janssen pharmaceuticals; and owns in CP Diagnostics LLC. Kristen E. Nordenholz, MD, has performed unrestricted research with Alere, Boehringer Ingelheim, and Genentech. The following authors declare no financial disclosures or relationships: Frances M. Russell, MD; Michael C. Plewa, MD; Peter B. Richman, MD; Howard A. Smithline, MD; Brian J O'Neil, MD; Daren M. Beam, MD; and Ronald Mastouri, MD.
ASJC Scopus subject areas
- Emergency Medicine